Robinhood Markets, Inc. vs Repligen Corporation Common Stock — how do they compare? Robinhood Markets, Inc. trades at $99.19 (market cap $99.37B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Robinhood Markets, Inc. is far larger — about 8.9× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Repligen Corporation Common Stock for 0 Days on average.
| HOOD | RGEN | |
|---|---|---|
Market Cap | $99.37B | $11.14B |
Volume | 14,977,713 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $147.08 | $194.57 |
52-Week Low | $65.16 | $102.87 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $105.91B | $11.02B |
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $101.08, down 7.45% in the last session, as investors digest mixed quarterly results. The stock shows neutral technical signals with support at $108 and resistance at $110. Fundamentally, the company demonstrates strong revenue growth from $3.0B in 2024 to $4.5B in 2025, with robust 42% net margins, though valuation multiples remain elevated with a P/E of 48.9. Recent announcements include plans for 24/7 stock trading and expanded crypto offerings.
Outlook remains positive with 77% analyst buy ratings and a $138.60 consensus price target implying 37% upside. Key opportunities include market share gains from new trading features, while risks involve high valuation sensitivity and regulatory scrutiny over leveraged crypto products. The Q3 2026 earnings report on October 27 will be critical for validating growth trajectory.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →